Two phase 3 trials in China of Gilead’s remdesivir as a COVID-19 treatment have been suspended because of the lack of eligible patients.
One trial in adults with severe COVID-19 only enrolled 237 patients, just over half of its 452-enrollment target. The second trial for mild-to-moderate cases aimed to enroll 308 patients but fell short of that number.
Both trials began in February and were suspended on April 10, weeks before their anticipated close-out dates. Results of the trials have not yet been posted.